Is HCV Genotyping Cost-Effective Even When the Prevalences of Genotypes 2 and 3 are Low?

Tahan V., Ozaras R., Karaca C., Uraz S., EREN F., Danalioglu A., ...Daha Fazla

HEPATO-GASTROENTEROLOGY, cilt.56, ss.1425-1428, 2009 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56
  • Basım Tarihi: 2009
  • Dergi Adı: HEPATO-GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1425-1428
  • Anahtar Kelimeler: Hepatitis C, Genotyping, Cost-effectiveness, HEPATITIS-C VIRUS, INTERFERON-ALPHA-2B PLUS RIBAVIRIN, INITIAL TREATMENT, RANDOMIZED-TRIAL, TURKISH PATIENTS, INFECTION, STEATOSIS
  • Marmara Üniversitesi Adresli: Evet

Özet

Background/Aims: The management of chronic hepatitis C virus (HCV) infection is costly. Genotyping determines the indication, probability of response.. and duration of treatment and the dose of ribavirin. Although genotyping is accepted cost-effective, the cost of genotyping in all of the patients to find out a minority may offset the gain.